- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 17-09-2025: Press Release
17-09-2025 | 01:05 pm
17-09-2025 | 01:05 pm
Lupin gains U.S. FDA approval for its Lenalidomide Capsules, a generic for Revlimid®. This drug, for multiple myeloma, addresses a $751.1 Cr annual U.S. market, signaling a substantial growth opportunity.
No comments yet. Be the first to comment!